DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
- Author(s):
- Henricks, L.M. (0000-0003-0141-7927); Lunenburg, C.A.T.C. (0000-0003-0173-9803); Man, F.M. de; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; Creemers, G.J.; Baars, A.; Dezentje, V.O.; Imholz, A.L.T.; Jeurissen, F.J.F.; Portielje, J.E.A.; Jansen, R.L.H.; Hamberg, P.; Tije, A.J. ten; Droogendijk, H.J.; Koopman, M.; Nieboer, P.; Poel, M.H.W. van de; Mandigers, C.M.P.W.; Rosing, H.; Beijnen, J.H.; Werkhoven, E. van; Kuilenburg, A.B.P. van; Schaik, R.H.N. van; Mathijssen, R.H.J.; Swen, J.J.; Gelderblom, H.; Cats, A.; Guchelaar, H.J. (0000-0002-7085-1383); Schellens, J.H.M.
- Published
- 2018
- Publication type
- Article / Letter to editor
- Date issued
- 2018-11-30
- Language
- English
- Is part of
- The Lancet Oncology (2018), Vol. 19, no. 11, p. 1459-1467
- hdl
- 1887/95617
- doi
- 10.1016/S1470-2045(18)30686-7